These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 19949399)

  • 1. Telavancin.
    Corey GR; Stryjewski ME; Weyenberg W; Yasothan U; Kirkpatrick P
    Nat Rev Drug Discov; 2009 Dec; 8(12):929-30. PubMed ID: 19949399
    [No Abstract]   [Full Text] [Related]  

  • 2. Antimicrobial development in the era of emerging resistance.
    Sorlozano A; Carrasco C; Cabeza J; Villegas E; Gutierrez J
    Mini Rev Med Chem; 2009 Jul; 9(8):938-55. PubMed ID: 19601889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regional analysis of telavancin and comparator antimicrobial activity against multidrug-resistant Staphylococcus aureus collected in the USA 2014-2016.
    Duncan LR; Smith CJ; Flamm RK; Mendes RE
    J Glob Antimicrob Resist; 2020 Mar; 20():118-123. PubMed ID: 31325617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Telavancin for the treatment of methicillin-resistant Staphylococcus aureus infections.
    Rodvold KA
    Clin Infect Dis; 2015 Sep; 61 Suppl 2():S35-7. PubMed ID: 26316556
    [No Abstract]   [Full Text] [Related]  

  • 5. In vitro activity of telavancin against a contemporary worldwide collection of Staphylococcus aureus isolates.
    Mendes RE; Moet GJ; Janechek MJ; Jones RN
    Antimicrob Agents Chemother; 2010 Jun; 54(6):2704-6. PubMed ID: 20385851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Telavancin: the long and winding road from discovery to food and drug administration approvals and future directions.
    Wenzler E; Rodvold KA
    Clin Infect Dis; 2015 Sep; 61 Suppl 2():S38-47. PubMed ID: 26316557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Introduction: fusidic acid enters the United States.
    Moellering RC; Corey GR; Grayson ML
    Clin Infect Dis; 2011 Jun; 52 Suppl 7():S467-8. PubMed ID: 21546622
    [No Abstract]   [Full Text] [Related]  

  • 8. Real-world use of telavancin in the treatment of osteomyelitis.
    Saravolatz LD; Cleveland KO; Rikabi K; Hassoun A; Reilly J; Johnson LB; Spak C; Valenti S; Szpunar S
    Diagn Microbiol Infect Dis; 2019 Oct; 95(2):185-190. PubMed ID: 31256939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ceftaroline fosamil for the treatment of acute bacterial skin and skin structure infections.
    Beresford E; Biek D; Jandourek A; Mawal Y; Riccobene T; Friedland HD
    Expert Rev Clin Pharmacol; 2014 Mar; 7(2):123-35. PubMed ID: 24494793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Telavancin: a novel lipoglycopeptide for serious gram-positive infections.
    Laohavaleeson S; Kuti JL; Nicolau DP
    Expert Opin Investig Drugs; 2007 Mar; 16(3):347-57. PubMed ID: 17302529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of telavancin in the treatment of MRSA infections in hospital.
    Bassetti M; Mikulska M; Righi E; Nicolini L; Viscoli C
    Expert Opin Investig Drugs; 2009 Apr; 18(4):521-9. PubMed ID: 19335280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of telavancin against Gram-positive isolates from complicated skin and skin structure infections: results from 2 phase 3 (ATLAS) clinical studies.
    Krause KM; Barriere SL; Kitt MM; Benton BM
    Diagn Microbiol Infect Dis; 2010 Oct; 68(2):181-5. PubMed ID: 20846593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Skin and soft-tissue infections: a critical review and the role of telavancin in their treatment.
    Cardona AF; Wilson SE
    Clin Infect Dis; 2015 Sep; 61 Suppl 2():S69-78. PubMed ID: 26316560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful treatment of methicillin-resistant Staphylococcus aureus endocarditis with telavancin.
    Nace H; Lorber B
    J Antimicrob Chemother; 2010 Jun; 65(6):1315-6. PubMed ID: 20375035
    [No Abstract]   [Full Text] [Related]  

  • 15. Telavancin.
    Lyseng-Williamson KA; Blick SK
    Drugs; 2009; 69(18):2607-20. PubMed ID: 19943710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Telavancin: mechanisms of action, in vitro activity, and mechanisms of resistance.
    Karlowsky JA; Nichol K; Zhanel GG
    Clin Infect Dis; 2015 Sep; 61 Suppl 2():S58-68. PubMed ID: 26316559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Telavancin for the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis.
    Twilla JD; Gelfand MS; Cleveland KO; Usery JB
    J Antimicrob Chemother; 2011 Nov; 66(11):2675-7. PubMed ID: 21831987
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparative efficacy of telavancin and daptomycin in experimental endocarditis due to multi-clonotype MRSA strains.
    Xiong YQ; Abdelhady W; Tang C'; Bayer AS
    J Antimicrob Chemother; 2016 Oct; 71(10):2890-4. PubMed ID: 27353467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin.
    Zhanel GG; Calic D; Schweizer F; Zelenitsky S; Adam H; Lagacé-Wiens PR; Rubinstein E; Gin AS; Hoban DJ; Karlowsky JA
    Drugs; 2010 May; 70(7):859-86. PubMed ID: 20426497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of Telavancin against Staphylococcus aureus Isolates, Including Those with Decreased Susceptibility to Ceftaroline, from Cystic Fibrosis Patients.
    Roch M; Varela MC; Taglialegna A; Rose WE; Rosato AE
    Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29914961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.